Celldex shares rise 2% as Phase 3 study completes ahead of schedule
Barzolvolimab targets $7.6bn chronic spontaneous urticaria market with topline data due Q4 2026
Celldex Therapeutics shares climbed 2.1% to $24.84 on Wednesday after the biotechnology company completed enrollment in two pivotal Phase 3 studies of its experimental treatment barzolvolimab for chronic spontaneous urticaria, a chronic skin condition affecting an estimated 1.8 million Americans.
The completion of enrollment across the EMBARQ-CSU1 and EMBARQ-CSU2 trials came six months ahead of schedule, with 1,939 patients recruited across 43 countries and more than 500 clinical sites. The studies represent the largest program ever conducted in antihistamine-refractory chronic spontaneous urticaria, including patients who have failed previous biologic treatments.
"The early completion of enrollment highlights the significant unmet need for better treatments in CSU and the enthusiasm from patients and physicians for barzolvolimab," Celldex said in a statement. The company now expects topline data from both studies in the fourth quarter of 2026, with plans to submit a Biologics License Application to US regulators in 2027.
Barzolvolimab is a first-in-class monoclonal antibody that targets mast cells—the root cause of chronic spontaneous urticaria—by inhibiting the KIT receptor crucial for mast cell function and survival. In Phase 2 studies, the treatment demonstrated rapid and profound efficacy, with up to 71% of patients achieving complete response at 52 weeks, benefits that were sustained even after therapy discontinuation.
The accelerated enrollment timeline reduces execution risk for Celldex as it advances toward what analysts project could become a major commercial opportunity. The chronic spontaneous urticaria treatment market across seven major markets is forecast to grow from approximately $2 billion in 2025 to $7.6 billion by 2034, representing a compound annual growth rate of 15.9%.
Celldex will compete in a market currently dominated by Novartis's Xolair (omalizumab) and more recently by Sanofi and Regeneron's Dupixent, which received FDA approval for chronic spontaneous urticaria in April 2025. Other competitors in late-stage development include Novartis's remibrutinib and Sanofi's rilzabrutinib.
Analysts remain broadly optimistic on Celldex's prospects, with 12 firms rating the stock a "buy" against just one "sell" recommendation. The consensus target price of $53.36 implies substantial upside from current levels, representing approximately 115% potential appreciation.
The positive development marks a significant milestone for a company that has undergone a dramatic strategic transformation. Celldex originally focused on oncology before pivoting in 2016 to inflammatory and autoimmune diseases following setbacks with cancer vaccine Rintega and antibody-drug conjugate glembatumumab vedotin. The shift appears to be bearing fruit, with barzolvolimab now serving as the company's lead asset across multiple mast cell-driven conditions.
Beyond chronic spontaneous urtitcaria, barzolvolimab is also in late-stage development for chronic inducible urticarias, including cold urticaria and symptomatic dermographism, where Phase 2 trials showed a single dose significantly reduced patients' ability to develop hives when exposed to triggers, with effects lasting a median of 57 to 77 days. Additional Phase 2 studies are ongoing in prurigo nodularis and atopic dermatitis.
From a financial perspective, Celldex appears well-positioned to fund development through the anticipated data readouts and regulatory submission. The company reported $583.2 million in cash as of September 30, 2025, which management expects will fund operations into the second half of 2027—providing sufficient runway to reach the planned topline data and BLA submission timeline.
"The robust balance sheet and long cash runway are seen as de-risking factors for its investment profile," according to recent analysis. The company's net loss for the third quarter of 2025 was $67 million, with research and development expenses of $62.9 million driven primarily by the barzolvolimab clinical trial program and manufacturing activities.
The two Phase 3 studies are randomized, double-blind, placebo-controlled trials evaluating two dosing regimens of barzolvolimab: 150 mg every four weeks and 300 mg every eight weeks. The primary endpoint measures the clinical effect in reducing urticaria activity as measured by the weekly urticaria activity score at week 12. The studies are designed to detect clinically meaningful differences between active arms versus placebo both in the overall population and specifically in patients refractory to omalizumab.
A global Phase 3b long-term extension study is also ongoing for patients completing the EMBARQ-CSU trials, which could provide additional data supporting sustained efficacy and safety should barzolvolimab successfully navigate the regulatory approval process.